Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41392-021-00525-3 http://scihub22266oqcxt.onion/10.1038/s41392-021-00525-3 33686064!7938043!33686064     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Signal+Transduct+Target+Ther 2021 ; 6 (1): 113 Nephropedia Template TP {{tp|p=33686064|t=2021. The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity |pdf=|usr=}}{{33686064}} gab.com Text The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity JO: Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=33686064 #FOAvip The adaptive immunity that protects patients from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is not well characterized. In particular, the asymptomatic patients have been found to induce weak and transient SARS-CoV-2 antibody responses, but the underlying mechanisms remain unknown; meanwhile, the protective immunity that guide the recovery of these asymptomatic patients is elusive. Here, we characterized SARS-CoV-2-specific B-cell and T-cell responses in 10 asymptomatic patients and 64 patients with other disease severity (mild, n = 10, moderate, n = 32, severe, n = 12) and found that asymptomatic or mild symptomatic patients failed to mount virus-specific germinal center (GC) B cell responses that result in robust and prolonged humoral immunity, assessed by GC response indicators including follicular helper T (T(FH)) cell and memory B cell responses as well as serum CXCL13 levels. Alternatively, these patients mounted potent virus-specific T(H)1 and CD8(+) T cell responses. In sharp contrast, patients of moderate or severe disease induced vigorous virus-specific GC B cell responses and associated T(FH) responses; however, the virus-specific T(H)1 and CD8(+) T cells were minimally induced in these patients. These results, therefore, uncovered the protective immunity in asymptomatic patients and also revealed the strikingly dichotomous and incomplete humoral and cellular immune responses in COVID-19 patients with different disease severity, providing important insights into rational design of effective COVID-19 vaccines. Twit Text FOAVip The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity ????Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=33686064 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33686064 #FOAvip English Wikipedia <ref>{{Cite pmid|33686064}}</ref> The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity #MMPMID33686064 Gao L; Zhou J; Yang S; Wang L; Chen X; Yang Y; Li R; Pan Z; Zhao J; Li Z; Huang Q; Tang J; Hu L; Liu P; Zhang G; Chen Y; Ye L Signal Transduct Target Ther 2021[Mar]; 6 (1): 113 PMID33686064show ga The adaptive immunity that protects patients from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is not well characterized. In particular, the asymptomatic patients have been found to induce weak and transient SARS-CoV-2 antibody responses, but the underlying mechanisms remain unknown; meanwhile, the protective immunity that guide the recovery of these asymptomatic patients is elusive. Here, we characterized SARS-CoV-2-specific B-cell and T-cell responses in 10 asymptomatic patients and 64 patients with other disease severity (mild, n = 10, moderate, n = 32, severe, n = 12) and found that asymptomatic or mild symptomatic patients failed to mount virus-specific germinal center (GC) B cell responses that result in robust and prolonged humoral immunity, assessed by GC response indicators including follicular helper T (T(FH)) cell and memory B cell responses as well as serum CXCL13 levels. Alternatively, these patients mounted potent virus-specific T(H)1 and CD8(+) T cell responses. In sharp contrast, patients of moderate or severe disease induced vigorous virus-specific GC B cell responses and associated T(FH) responses; however, the virus-specific T(H)1 and CD8(+) T cells were minimally induced in these patients. These results, therefore, uncovered the protective immunity in asymptomatic patients and also revealed the strikingly dichotomous and incomplete humoral and cellular immune responses in COVID-19 patients with different disease severity, providing important insights into rational design of effective COVID-19 vaccines. |*Adaptive Immunity[MESH] |Adult[MESH] |B-Lymphocytes/*immunology/pathology[MESH] |CD8-Positive T-Lymphocytes/*immunology/pathology[MESH] |COVID-19/*immunology/pathology[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |SARS-CoV-2/*immunology[MESH] |Severity of Illness Index[MESH]The dichotomous and incomplete adaptive immunity in COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing